XERS
Income statement / Annual
Last year (2024), Xeris Biopharma Holdings, Inc.'s total revenue was $203.07 M,
an increase of 23.89% from the previous year.
In 2024, Xeris Biopharma Holdings, Inc.'s net income was -$54.84 M.
See Xeris Biopharma Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$203.07 M |
$163.91 M |
$110.25 M |
$49.59 M |
$20.44 M |
$2.72 M |
$2.47 M |
$1.56 M |
$1.08 M |
| Cost of Revenue |
$36.83 M
|
$28.65 M
|
$22.63 M
|
$13.32 M
|
$9.33 M
|
$1.60 M
|
$42.00 K
|
$4.00 K
|
$8.00 K
|
| Gross Profit |
$166.24 M
|
$135.27 M
|
$87.61 M
|
$36.27 M
|
$11.11 M
|
$1.12 M
|
$2.42 M
|
$1.55 M
|
$1.07 M
|
| Gross Profit Ratio |
0.82
|
0.83
|
0.79
|
0.73
|
0.54
|
0.41
|
0.98
|
1
|
0.99
|
| Research and Development Expenses |
$25.56 M
|
$22.34 M
|
$20.97 M
|
$25.16 M
|
$20.92 M
|
$60.44 M
|
$40.65 M
|
$20.17 M
|
$10.24 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$21.11 M
|
$8.02 M
|
$4.06 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$163.48 M
|
$146.10 M
|
$137.75 M
|
$125.72 M
|
$73.73 M
|
$63.06 M
|
$21.11 M
|
$8.02 M
|
$4.06 M
|
| Other Expenses |
$10.84 M
|
$10.84 M
|
$10.84 M
|
$550.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$1.00 K
|
-$5.00 K
|
| Operating Expenses |
$199.88 M
|
$179.28 M
|
$169.55 M
|
$151.43 M
|
$94.65 M
|
$123.50 M
|
$61.77 M
|
$28.18 M
|
$14.30 M
|
| Cost And Expenses |
$236.72 M
|
$207.92 M
|
$192.19 M
|
$164.75 M
|
$103.98 M
|
$125.10 M
|
$61.81 M
|
$28.19 M
|
$14.31 M
|
| Interest Income |
$5.32 M
|
$4.75 M
|
$2.58 M
|
$313.00 K
|
$4.47 M
|
$2.81 M
|
$1.61 M
|
$124.00 K
|
$5.00 K
|
| Interest Expense |
$33.18 M
|
$26.61 M
|
$14.10 M
|
$7.18 M
|
$7.36 M
|
$7.16 M
|
$2.55 M
|
$2.00 K
|
$2.00 K
|
| Depreciation & Amortization |
$12.63 M
|
$13.16 M
|
$12.67 M
|
$1.88 M
|
$1.47 M
|
$1.08 M
|
$320.00 K
|
$177.00 K
|
$116.00 K
|
| EBITDA |
-$13.99 M |
-$23.74 M |
-$69.31 M |
-$113.67 M |
-$79.12 M |
-$117.80 M |
-$57.22 M |
-$26.38 M |
-$13.09 M |
| EBITDA Ratio |
-0.07
|
-0.14
|
-0.63
|
-2.29
|
-3.87
|
-43.28
|
-23.21
|
-16.95
|
-12.18
|
| Operating Income Ratio |
-0.17
|
-0.27
|
-0.74
|
-2.32
|
-4.09
|
-44.96
|
-24.07
|
-17.11
|
-12.31
|
| Total Other Income/Expenses Net |
-$23.46 M
|
-$19.49 M
|
-$14.14 M
|
-$7.57 M
|
-$7.70 M
|
-$3.66 M
|
-$736.00 K
|
$75.00 K
|
$22.00 K
|
| Income Before Tax |
-$57.10 M
|
-$63.50 M
|
-$96.08 M
|
-$122.73 M
|
-$91.25 M
|
-$126.04 M
|
-$60.08 M
|
-$26.55 M
|
-$13.21 M
|
| Income Before Tax Ratio |
-0.28
|
-0.39
|
-0.87
|
-2.47
|
-4.47
|
-46.3
|
-24.37
|
-17.07
|
-12.29
|
| Income Tax Expense |
-$2.27 M
|
-$1.25 M
|
-$1.42 M
|
$0.00
|
-$110.00 K
|
-$458.00 K
|
$0.00
|
$1.00 K
|
-$3.00 K
|
| Net Income |
-$54.84 M
|
-$62.26 M
|
-$94.66 M
|
-$122.73 M
|
-$91.14 M
|
-$125.58 M
|
-$60.08 M
|
-$26.55 M
|
-$13.21 M
|
| Net Income Ratio |
-0.27
|
-0.38
|
-0.86
|
-2.47
|
-4.46
|
-46.14
|
-24.37
|
-17.07
|
-12.29
|
| EPS |
-0.37 |
-0.45 |
-0.7 |
-1.55 |
-2.14 |
-3.49 |
-4.99 |
-13.09 |
-7.17 |
| EPS Diluted |
-0.37 |
-0.45 |
-0.7 |
-1.55 |
-2.14 |
-3.49 |
-4.99 |
-13.09 |
-7.17 |
| Weighted Average Shares Out |
$146.77 M
|
$137.67 M
|
$135.63 M
|
$79.03 M
|
$42.64 M
|
$26.11 M
|
$12.05 M
|
$2.03 M
|
$1.84 M
|
| Weighted Average Shares Out Diluted |
$146.77 M
|
$137.67 M
|
$135.63 M
|
$79.03 M
|
$42.64 M
|
$26.11 M
|
$12.05 M
|
$2.03 M
|
$1.84 M
|
| Link |
|
|
|
|
|
|
|
|
|
